This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bet on These 4 Biotech Stocks With Bright Prospects
by Ekta Bagri
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.
9 Meters (NMTR) Up on Results From Bowel Syndrome Candidate
by Zacks Equity Research
9 Meters (NMTR) reports a positive top line from a phase II study of vurolenatide, being evaluated for short bowel syndrome in adults and a successful end-of-phase II meeting with the FDA.
DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold
by Zacks Equity Research
DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA. Stock declines.
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and vTv Therapeutics (VTVT) have performed compared to their sector so far this year.
Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study
by Zacks Equity Research
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
Akero Therapeutics (AKRO) Up on Positive Data from NASH Study
by Zacks Equity Research
Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.
Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.
Ideaya (IDYA) Up on Interim Data from Mid-Stage Eye Cancer Study
by Zacks Equity Research
Ideaya Biosciences (IDYA) reports positive interim results from its mid-stage study, evaluating darovasertib in combination with Pfizer's Xalkori (crizotinib) in metastatic uveal melanoma. Stock up.
Axsome (AXSM) Initiates Late-Stage Alzheimer's Agitation Study
by Zacks Equity Research
Axsome Therapeutics (AXSM) enrolls the first patient in a late-stage study of AXS-05 for Alzheimer's disease agitation.
Is Argenx (ARGX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
by Zacks Equity Research
Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine.
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose
by Zacks Equity Research
Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product
by Zacks Equity Research
Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.
Does Immunocore Holdings PLC Sponsored ADR (IMCR) Have the Potential to Rally 45% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 44.9% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Momentum in Immunocore Holdings PLC Sponsored ADR (IMCR) Should Keep going
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
What Makes Immunocore Holdings PLC Sponsored ADR (IMCR) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Immunocore Holdings PLC Sponsored ADR (IMCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Bellicum Pharmaceuticals (BLCM) have performed compared to their sector so far this year.
Wall Street Analysts Think Immunocore Holdings PLC Sponsored ADR (IMCR) Could Surge 32%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 31.8% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why "Trend" Investors Would Love Betting on Immunocore Holdings PLC Sponsored ADR (IMCR)
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Is Immunocore (IMCR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Jazz Pharmaceuticals (JAZZ) have performed compared to their sector so far this year.
Zacks.com featured highlights Immunocore Holdings, Franklin Covey, Ardmore Shipping, StoneX and Alliance Resource
by Zacks Equity Research
Immunocore Holdings, Franklin Covey, Ardmore Shipping, StoneX and Alliance Resource have been highlighted in this Screen of The Week article.
Here's What Could Help Immunocore Holdings PLC Sponsored ADR (IMCR) Maintain Its Recent Price Strength
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
5 Stocks With Recent Price Strength to Gain From July Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, FC, ASC, SNEX and ARLP.
Wall Street Analysts Think Immunocore Holdings PLC Sponsored ADR (IMCR) Could Surge 29%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 29.4% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has McKesson (MCK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.